A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease

Trial Profile

A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Feb 2014 Planned number of patients changed from 65 to 56 as reported by ClinicalTrials.gov.
    • 13 Feb 2014 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top